Identification of a DNA Methylome Profile of Esophageal Squamous Cell Carcinoma and Potential Plasma Epigenetic Biomarkers for Early Diagnosis

Xufeng Li1,*, Fuyou Zhou2,*, Chunyu Jiang1, Yinuo Wang3, Yanqiang Lu3, Fei Yang3, Nengchao Wang2, Haijun Yang2, Yanfang Zheng1,*, Jiren Zhang1,3*

1 Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, China, 2 Anyang Cancer Hospital, Anyang, China, 3 Institute of Targeted Molecular Medicine, Shanghai, China

Abstract

DNA methylation is a critical epigenetic mechanism involved in key cellular processes. Its deregulation has been linked to many human cancers including esophageal squamous cell carcinoma (ESCC). This study was designed to explore the whole methylation status of ESCC and to identify potential plasma biomarkers for early diagnosis. We used Infinium Methylation 450k array to analyze ESCC tissues (n = 4), paired normal surrounding tissues (n = 4) and normal mucosa from healthy individuals (n = 4), and combined these with gene expression data from the GEO database. One hundred and sixty eight genes had differentially methylated CpG sites in their promoter region and a gene expression pattern inverse to the direction of change in DNA methylation. These genes were involved in several cancer-related pathways. Three genes were validated in additional 42 ESCC tissues and paired normal surrounding tissues. The methylation frequency of EPB41L3, GPX3, and COL14A1 were higher in tumor tissues than in normal surrounding tissues (P < 0.017). The higher methylation frequency of EPB41L3 was correlated with larger tumor size (P = 0.044) and advanced pT tumor stage (P = 0.001). The higher methylation frequency of GPX3 and COL14A1 were correlated with advanced pN tumor stage (P = 0.001 and P < 0.001). The methylation frequency of EPB41L3, GPX3, and COL14A1 genes were only found in ESCC patients’ plasma, but not in normal individuals upon testing 42 ESCC patients and 50 healthy individuals. Diagnostic sensitivity was increased when methylation of any of the 3 genes were counted (64.3% sensitivity and 100% specificity). These differentially methylated genes in plasma may be used as biomarkers for early diagnosis of ESCC.

Introduction

Esophageal cancer (EC) is the eighth most common cancer worldwide and the sixth most common cause of death from cancer [1]. Esophageal cancer usually occurs as either squamous cell carcinoma in the middle or upper one-third of the esophagus, or as adenocarcinoma in the lower one-third or junction of the esophagus and stomach. In the highest risk area, which stretches from northern Iran through the central Asian republics to North-Central China and often referred to as the “esophageal cancer belt”, 90% of cases are squamous cell carcinomas [2]. Esophageal squamous cell carcinoma (ESCC), which is the major histological type of esophageal cancer, is one of the most aggressive malignant tumors. Despite advances in diagnostic methods and combined treatment modalities, the majority of esophageal squamous cell carcinomas (ESCC) are diagnosed at advanced stages and overall 5-year survival rate is still poor. In sharp contrast, the 5-year survival rate for early-stage ESCC patients was 100% after endoscopic mucosectomy. Therefore, it is imperative to further understand the underlying molecular mechanism of ESCC, and to identify effective biomarkers for early diagnosis and potential targets for prevention and therapy.

Epigenetics, one of the most promising and expanding fields in current biomedical research, refers to stable alterations in gene expression with no underlying modifications in the genetic sequence. Both genetic and epigenetic aberrations are linked by intricate crosstalk, and can either individually or in synergy lead to the development of cancer. One study shows that up-regulation of FOXM1 in normal human cells can orchestrate a DNA methylation signature that mimics the cancer methylome landscape [3]. Accumulating evidence suggests that epigenetic changes such as alternations in DNA methylation play a crucial role in ESCC [4,5]. Numerous tumor-related genes, including FHit [6], RARb [6–8], CDKN2A [7,9,10], MGMT [7,9,11], RASSF1 [6], RBP1 [7,8], CDKN2AB [10], MT1G [7], MLH1 [10,12], CDH1 [13], VHL [6], MT3 [14], C2orf40 [13], RPRM [16], CLND3...
and controls. Methylation of the circulating cell-free DNA in patients’ plasma candidate genes is useful for diagnosing ESCC, we also tested the tissues. In order to evaluate whether the methylation status of the 3 analysis using additional ESCC tumor tissues and adjacent normal epigenomic profiling studies [20]. Furthermore, aberrant DNA methylation usually occurs somatically in cancers and can be detected in the blood circulation, so it may serve as a novel marker for cancer. For example, the methylation of some tumor related genes such as p16, DAPK, RAR-β, CDH1, and RASSF1A have been detected in circulating cell-free DNA [21]. In the current study, we analyzed global methylation profiling of ESCC and normal adjacent tissue in Chinese cancer patients and esophageal mucosa from Chinese healthy individuals, using Infinium Methylation 450K array. After analysis of the methylation differences and then in combination with independent gene expression data using BRB (Biometrics Research Branch)-Array Tools of the National Cancer Institute, a set of genes that are deregulated by aberrant DNA methylation in ESCC was identified. We then focused on 3 aberrant DNA methylation genes—EPB41L3, GPRX3, and COL14A1, with validation analysis using additional ESCC tumor tissues and adjacent normal tissues. In order to evaluate whether the methylation status of the 3 candidate genes is useful for diagnosing ESCC, we also tested the methylation of the circulating cell-free DNA in patients’ plasma and controls.

Patients and methods

Clinical samples

All ESCC patients and normal volunteers were gathered from Anyang Cancer Hospital, Henan province, China, from June to September in the year 2012. Tumors and paired adjacent non-tumor tissue samples from four ESCC patients were used for Infinium Methylation 450k array analysis. These 4 patients are relatively early stage patients (stage IA to stage IIA), and their clinical characters are listed in Table 1. Following surgery, the tissue samples were promptly frozen in liquid nitrogen and then stored at −80°C until use. Additional 42 ESCC patients were gathered to acquire blood samples before surgery, tumor and adjacent non-tumor tissues following surgery. These patients included 27 males and 15 females whose ages ranged from 42 to 74 years (mean ± SD, 63±7.36), with 8 IIIA, 12 IIIB, 16 IIA, and 6 IIB patients. None of the patients had a history of chemotherapy or radiotherapy before surgery. The diagnosis was confirmed as squamous cell carcinoma by pathological examination. Tumor stages were evaluated according to the TNM classification of the American Joint Committee on Cancer (AJCC). Four tissue samples collected from healthy volunteers who have no upper digestive tract cancer diagnosed by endoscope, were used for Infinium Methylation 450k array analysis.

Blood samples were collected from 42 patients before surgery as mentioned above, and plasma was separated twice by centrifugation at 1000 x g for 5 min and stored at −80°C until use. In addition, plasma samples from 50 healthy volunteers were used as negative controls. The healthy volunteers (24 males and 26 females) ranged in age from 17 to 75 years (mean ± SD, 52.7±11.5). All participants signed an informed consent and information was obtained using a standardized questionnaire, including data on tobacco smoking, alcohol drinking, and family history. An individual was classified as a smoker if he or she smoked at least one cigarette per day for more than one year. An individual was classified as a drinker if he or she drank alcoholic beverages five times per week for more than one year. Family history of cancer was defined as positive when at least one of the patient’s first-degree relatives was definitely diagnosed with cancer. This study was approved by the ethics committee of the Anyang Cancer Hospital in Henan province in China. Written Informed consent have been obtained from all the participants and kept as records submitted back to ethics committee. For minor participants less than 18 years old (2 healthy volunteers aged 17), written informed consent was obtained from guardians. The ethics committee approved the consent procedure.

DNA methylation assay

Genomic DNA was extracted from tissue samples using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Cell-free plasma DNA was isolated using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Extracted DNA was bisulfite-modified using EZ-DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA).

Genome-wide DNA methylation profiling was performed using the Infinium Methylation 450K array (Illumina, San Diego, CA, USA). Genomic DNAs were modified with the EZ-DNA methylation kit (Zymo Research, Orange, CA, USA) following recommendations from Illumina. The Illumina Infinium assay was also conducted according to the manufacturer’s protocol.

Table 1. Clinic information of the 4 ESCC patients whose samples were used for methylation array.

| specimen | Age (year) | gender | TNM* | G(histologic grade) | Tumor location | stage |
|----------|------------|--------|------|---------------------|----------------|-------|
| T1 and S1 | 61         | male   | T2N0M0 | G1                  | Lower          | I B   |
| T2 and S2 | 63         | male   | T1N0M0 | G2                  | Middle         | I B   |
| T3 and S3 | 65         | female | T1N0M0 | G1                  | Middle         | I A   |
| T4 and S4 | 65         | male   | T2N0M0 | G1                  | Middle         | II A  |

*Tumor stages were evaluated according to the TNM classification of the American Joint Committee on Cancer (AJCC). doi:10.1371/journal.pone.0103162.t001
Methylation-specific PCR (MSP) was used to examine the methylation status of EPB41L3, COL1A1, and GPX3, as described previously in the literature [22]. The primer sequences of EPB41L3 were described in the literature [23]. The primer sequences of GPX3 and COL1A1 were designed by an online tool as described in the literature [24]. Primer sequences and conditions are listed in Table 2. SssI-treated normal lymphocyte DNA was used as positive control. Positive controls and negative controls (without DNA) were performed in each set of MSP and each MSP was repeated three times. The MSP products were separated electrophoretically on 2% agarose gels.

Expression data of ESCC
Gene expression data (GSE20347) of ESCC that was based on the Affymetrix array were downloaded from Gene Expression Omnibus of National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20347), a public data repository [25]. These expression data generated using 17 tumor tissues and 17 paired adjacent normal tissue. The downloaded data was imported to BRB-Array Tools for statistical analysis.

Statistical analysis
Raw Infinium Methylation 450K array data, which have been deposited in NCBI’s Gene Omnibus (GEO) repository and are accessible through GEO’s Gene Expression Omnibus (GSE52826), were obtained using GenomeStudio software (Illumina) after scanning the BeadChips. Differentially methylated CpG sites were identified by analyzing the CpG island microarray data with the class comparison feature of BRB-Array Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html). Unsupervised hierarchical clustering analysis was also conducted using the BRB-Array tool. M-value, which is the log2 ratio of methylated probe intensity and unmethylated probe intensity, is used to measure the methylation level. M-value method is approximately homoscedastic in the entire methylation range, so it is more statistically valid in differential and other statistical analysis [26]. In addition, we also expressed the expression data of ESCC (GSE20347) with the class comparison tool of BRB-Array in order to correct possible false positives from multiple tests (α = 0.05).

Results
Identification of differentially methylated CpG sites in ESCC
Genome-wide DNA methylation profiling was conducted using the Infinium Methylation 450K array. We evaluated 4 paired tumor samples and corresponding adjacent normal tissues, along with 4 normal tissue samples from healthy volunteers that were originally collected from Anyang Cancer Hospital in Henan province in China. The methylation array data was submitted to Gene Expression Omnibus (GEO), NCBI (National Center for Biotechnology Information) (data number GSE52826). After normalization, all 12 samples showed very similar signal distributions (Figure 1), which means with both hypermethylation and hypomethylation changes, tumor, adjacent normal and normal tissues are similar on overall methylation signals. While unsupervised hierarchical clustering on the entire DNA methylation data set showed the 2 clusters which were mainly composed by two different phenotypes: tumor and normal (including normal and adjacent normal tissues) (Figure 2). This indicated that ESCC and normal samples might have different DNA methylation characters and patterns. In addition, the results also showed that there were discovery rate (FDR) in order to correct possible false positives from multiple tests (α = 0.05). We also subsequently calculated a fold change of M value that had greater or equal to 2 between 2 comparison groups. Therefore, a differentially methylated CpG (DMC) was defined as a CpG site with a FDR-adjusted P value < 0.05 and a fold change of M-value between 2 comparison groups greater or equal to 2. Similarly, we defined the difference of expression data as a FDR adjusted P value < 0.05 and a fold change between 2 comparison groups greater or equal to 2. Pathway analysis was performed using DAVID Bioinformatics Resource.

IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA) was used for other statistical analysis. Statistical analysis was performed using Pearson chi-square test or the Fisher exact test for differences between groups. ROC curve analysis was used to determine AUC, sensitivity, and specificity of circulating cell-free plasma DNA methylation. P value < 0.05 were considered statistically significant. All reported P values were based on 2-sided tests. Bonferroni adjustments were estimated to correct for multiple tests.

Table 2. Primer and Probe Sequences of Genes Related to Esophageal Squamous Cell Carcinoma.

| Genes   | Primer sequences | Annealing temperature (°C) | Product size (base pair) |
|---------|------------------|-----------------------------|-------------------------|
| EPB41L3 | M Sense:TTTGTTTTTTCTGATCGGT 62 | 110 |
|         | U Sense:AGGTGTTTTTTTGTATCGGT 64 | 114 |
| GPX3    | M Sense:CCTCTGTATTTTGAAATTTGTC 62 | 140 |
|         | U Sense:CCTCTGTATTTTGAAATTTGTC 62 | 140 |
| COL1A1  | M Sense:GTGCAGGCGGGTGGTTTTTAATTTTC 62 | 167 |
|         | U Sense:GATTGCGGCTTTTTTAGTTTGT 62 | 168 |

doi:10.1371/journal.pone.0103162.t002
some differences in DNA methylation profiles between adjacent normal and normal tissues (Figure 2).

To identify aberrant differential methylated CpG (DMC) in ESCC, we performed statistical analysis to pare down the selection of CpG sites based on DNA methylation differences (Figure 3). We put normal and adjacent normal (non-tumor) tissues into one group and compared with tumor tissues. A total of 66,857 CpG sites showed statistical significance with false discovery rate (FDR) adjusted P<0.05 and at least two-fold methylation change between ESCC and normal/adjacent normal samples. These 66,857 DMCs included 18,146 hypermethylated CpG sites (hyper-DMCs) and 48,711 hypomethylated CpG sites (hypo-DMCs) in tumors compared with normal/adjacent normal tissues. Interestingly, 75.3% of hyper-DMCs (13,656 CpG sites) were located in CGI, CGI shores, or CGI shelves, but only 37.3% of hypo-DMCs were found in these regions.

Combination analysis between methylation data and expression data of ESCC

To find aberrant DNA methylation that may cause gene expression change in ESCC, we correlatively analyzed methylation data and expression data of ESCC downloaded from the GEO database. The methylation data analysis showed that a total of 66,857 DMCs included 17,197 CpG sites in proximal promoters, which were related to 6,200 genes (gene set 1). The expression data compared 17 ESCC tumor tissues and 17 paired adjacent normal tissues, and showed that there were 1,601 probe difference between ESCC and control, which were related to 1256 genes (gene set 2). There were 294 common genes between gene set 1 and gene set 2. Among the 294 genes, 168 genes showed inverse correlation between DNA methylation and expression change, which means when compared with normal tissue, they were either hypermethylated with lower expression, or hypomethylated with higher expression in tumor tissue (Figure 3). The heat map figure showed that these 168 genes were differently methylated between tumor and normal tissues (Figure 4). In addition, Figure 4 also showed that there were some differences in DNA methylation profiles between adjacent normal and normal tissues.

Based on the combination analysis result of the 168 genes, we further identified the pathway of these genes. The DAVID (Database for Annotation, Visualization, and Integrated Discovery v6.7) online bioinformatics analysis showed that these genes were majorly involved in 6 pathways in the KEGG (Kyoto Encyclopedia of Genes and Genomes) database, which include “focal adhesion”, “ECM-receptor interaction”, “axon guidance”, “pathways in cancer”, “apoptosis”, and “aldosterone-regulated sodium reabsorption”.

Figure 1. Boxplots of log ratio of 12 samples’ raw microarray data. After the log2 transfer and normalization, all samples showed very similar signal distributions.

doi:10.1371/journal.pone.0103162.g001

Figure 2. Unsupervised clustering of samples. Unsupervised hierarchical clustering on the entire DNA methylation data set showed the 2 clusters which were mainly composed by two different phenotypes: tumor and normal (including normal and adjacent normal tissues). This indicated that ESCC and normal samples might have different DNA methylation characters and patterns. In addition, there were some differences in DNA methylation profiles between adjacent normal and normal tissues.

doi:10.1371/journal.pone.0103162.g002
As we described above, the 168 genes were either hypermethylated with lower expression, or hypomethylated with higher expression in tumor tissue compared with normal tissue. We then calculated the ESCC to control ratio of DNA methylation and gene expression rate for each gene (data not shown), and picked up 3 genes with most significant difference between tumor and normal.

**EPB41L3**, **GPX3**, and **COL14A1** were chosen. We used methylation specific PCR (MSP) analysis to study DNA methylation status of **EPB41L3**, **GPX3**, and **COL14A1** genes in tumor and paired surrounding normal tissue from 42 ESCC patients (Figure 5). The unmethylated form of all genes was detected in all samples. The MSP analysis revealed that the methylation frequencies of **EPB41L3**, **GPX3**, and **COL14A1** in ESCC tumor samples were 59.5%, 54.8%, and 45.2%, respectively. The methylation frequencies of **EPB41L3**, **GPX3**, and **COL14A1** in normal surrounding tissue were 4.8%, 9.5%, and 11.9%, respectively. The frequencies of hypermethylated genes were significantly higher than that in paired surrounding normal tissues (P<0.01) (Table 3).

The relationship between the clinico-pathological parameters and DNA methylation patterns in the testing group cases was explored. Methylation of **EPB41L3** was more frequently seen in patients with tumor size ≤ 5 cm than in patients with tumor size < 5 cm (P = 0.044, Table 4). We also found that methylation of **EPB41L3** correlated significantly with the advanced pathologic tumor (pT) classification (P = 0.001, Table 4). The methylation frequencies of **GPX3** were lower in the pT1-2 and pN0-1 groups compared with the pT3 and pN2 groups, respectively. For the methylation of **COL14A1**, we observed a significant difference between males and females (P = 0.019, Table 4). In addition, methylation of **COL14A1** was much more frequent in the pN2 group compared to the pN0-1 group (P = 0.000, Table 4). We also found that the methylation of **COL14A1** was higher in moderately differentiated tumors than in well and poorly differentiated tumors. No significant correlations were observed between methylation of any gene with age, family history, smoking, or drinking.

**Figure 3. Combination analysis between DNA methylation data and gene expression data identified 168 differentially methylated genes in ESCC.** Methylation data analysis showed 66,857 DMCs, which related to 6,200 genes (gene set 1). Expression data analysis showed 1,601 probe differences between ESCC and control, which related to 1,256 genes (gene set 2). There were 294 common genes between gene set 1 and gene set 2. 168 genes were selected due to inverse correlation between DNA methylation and expression change.

doi:10.1371/journal.pone.0103162.g003
Hypermethylation status of **EPB41L3**, **GPX3**, and **COL14A1** in circulating cell-free plasma DNA and correlation with clinico-pathological parameters

The methylation status of **EPB41L3**, **GPX3**, and **COL14A1** genes were assessed in circulating cell-free plasma DNA in the 42 ESCC patients and 50 healthy individuals. The methylation frequency of **EPB41L3**, **GPX3**, and **COL14A1** were 31.0%, 40.5% and 31.0% in cancer patients’ plasma, respectively. Examples of MSP analysis are shown in Figure 5. We did not find methylation of the 3 genes in healthy individuals’ plasma. There were statistically significant differences of methylation of the 3 genes in circulating cell-free plasma DNA between cancer patients and healthy individuals group (Table 5).

We analyzed whether plasma DNA methylation was correlated with clinico-pathological parameters in 42 ESCC patients. Comparing pT3 with the pT1-2 group, we found that the methylation frequencies of **GPX3** and **COL14A1** were significantly higher in the pT3 group (P = 0.044 and P = 0.015, respectively) (Table 6). **EPB41L3** hypermethylation was correlated with advanced pN classification (pN2) (87.5% vs. 17.6%) (P < 0.001) (Table 6).

Evaluation of circulating cell-free plasma DNA methylation markers for early diagnosis of ESCC

To assess the clinical usefulness of plasma DNA methylation patterns as early diagnostic biomarkers of ESCC, we calculated their sensitivity and specificity using ROC (receiver operative characteristic) curve analysis. The sensitivity of the methylation status of **EPB41L3**, **GPX3**, and **COL14A1** genes were 31.0%, 40.5%, and 31.0%, respectively. The specificity of any of the 3 genes was 100% based on our data. The overall diagnostic sensitivity of 3 genes for ESCC, when at least 1 of the 3 genes was positive, rose to 64.3%, and the specificity remained 100% (AUC [area under the ROC curve] = 0.821, 95% CI [confidence interval] = 0.727–0.916, Table 7).

**Discussion**

Although epigenetic events have been implicated in esophageal cancer, genome-wide epigenetic deregulation and precise targets of aberrant DNA methylation during the development and progression of ESCC have not been defined. In this pilot study, we describe the methylation profile of Chinese ESCC patients. One hundred and sixty eight differentially methylated genes that were functionally deregulated in ESCC were identified. We validate methylation status of 3 genes from the 168 genes in
independent tumor and normal samples and evaluate their value for diagnosis of ESCC.

In this study, we have established a large-scale profile of promoter methylation in Chinese ESCC patients. We combined analysis the Infinium HD 450K methylation array data with gene expression array data. From this we identified a set of genes that have potential functional consequences owing to the aberrant promoter DNA methylation. The pathway analysis showed that these genes take part in tumor-related pathways which may play an important role in the development and progression of the disease. We chose 3 genes from 168 genes for validation in independent tissue samples and evaluated their significance in clinical diagnosis of ESCC. Therefore, our results not only strengthen the findings on the importance of aberrant DNA methylation in ESCC, but also provide a novel and more comprehensive signature of ESCC methylation.

We tested DNA methylation in more than 480,000 CpG sites using the Infinium HD 450K methylation array in ESCC samples, adjacent normal surrounding tissues, and normal mucosa of healthy individuals. An initial, unsupervised hierarchical analysis with all of the tested CpG sites showed that there are two main clusters: tumor and normal (including adjacent normal surrounding tissues and normal tissues from healthy individuals) (Figure 2). This indicates that tumors show different methylation profiles in comparison with normal tissues. This result supports the previous study of the ESCC DNA methylation profile using the GoldenGate bead array (Illumina, San Diego, CA, USA), which contains 1,505 CpG sites in 807 cancer-related genes [19]. Interestingly, our result also shows that adjacent normal surrounding tissues also have different DNA methylome patterns compared with normal tissues. We presume there may be field cancerization phenomenon existed in adjacent normal tissues. More studies need to be done to explore the detail mechanism of methylation difference between normal and adjacent normal tissues.

BRB-Array Tools is an integrated software system for the comprehensive analysis of DNA microarray experiments [27]. By class comparison using the BRB-Array Tools, we identified 66,857 differentially methylated CpG sites in ESCC. We chose to limit our analysis to the proximal promoter region because this region is well characterized for its effects of DNA methylation on gene silencing. This approach also allowed us to evaluate associations

Figure 5. Representative results of MSP analysis of the candidate genes. M, markers; N, negative control (water blank); P, positive control (universal methylated DNA); T, tumor tissue; S, paired surrounding normal tissue; TBP, blood plasma of tumor patients. Samples were scored as methylated when there was a clearly visible band with the methylated primers. doi:10.1371/journal.pone.0103162.g005

| Table 3. Frequency of Promoter Methylation for Individual Genes in Esophageal Squamous Cell Carcinoma Patients (n = 84). |
|---|---|---|
| Genes | Frequency of Methylation(%) | P value |
| **ESCC** | **ST** | |
| EPB41L3 | 59.5 | 4.8 | <0.001* |
| GPX3 | 54.8 | 9.5 | <0.001* |
| COL14A1 | 45.2 | 11.9 | 0.001* |

*ESCC, esophageal squamous cell carcinoma; ST, surrounding normal tissue; *statistical significance after multiple testing (P<0.01). doi:10.1371/journal.pone.0103162.t003
with gene expression changes based on an independent ESCC data set. The assumption is that inverse correlations between promoter methylation and gene expression may plausibly indicate a functional result of differential methylated genes identified in ESCC. This approach identified 168 genes in ESCC. Based on the combined analysis signature of methylation data and expression data, we identified the pathways that are specifically altered in this type of cancer. Our results suggested that these altered pathways may play pivotal role in ESCC tumorigenesis.

A candidate tumor suppressor gene, EPB41L3, on 18p11.3 was initially isolated by Tran et al using differential display analysis in a panel of non-small cell lung carcinoma when compared to matched normal tissue [28]. A growing body of evidence supports the role of tumor suppression of the EPB41L3 gene [29]. EPB41L3 interacts with cytoplasmic adaptor protein 14-3-3 [30], which is involved in signal transduction, cell cycle regulation, apoptosis, and malignancy [31], and may play a role in growth suppression. The expression of EPB41L3 was greatly reduced in

---

**Table 4.** Correlation Between DNA Hypermethylation and Clinico-pathological Parameters of Esophageal Squamous Cell Carcinoma Patients (n = 42).

| Frequency of methylation (%) | EPB41L3 | GPX3 | COL14A1 |
|-----------------------------|---------|------|---------|
| **Gender**                  |         |      |         |
| Male (n = 27)               | 55.6    | 51.9 | 44.4    |
| Female (n = 15)             | 66.7    | 60.0 | 46.7    |
| P value                     | 0.482   | 0.611| 0.890   |
| **Age group (year)**        |         |      |         |
| ≤60 (n = 11)                | 72.8    | 63.6 | 36.4    |
| ≥60 (n = 31)                | 54.8    | 51.6 | 48.4    |
| P value                     | 0.299   | 0.726| 0.726   |
| **Family history**          |         |      |         |
| Yes (n = 17)                | 60.0    | 56.0 | 48.0    |
| No (n = 25)                 | 58.8    | 52.9 | 41.2    |
| P value                     | 0.939   | 0.845| 0.663   |
| **Tumor size**              |         |      |         |
| ≤5 (n = 27)                 | 48.1    | 48.1 | 44.4    |
| >5 (n = 15)                 | 80.0    | 66.7 | 46.7    |
| P value                     | 0.044   | 0.248| 0.890   |
| **Differentiation**         |         |      |         |
| Well (n = 6)                | 50.0    | 16.7 | 16.7    |
| Moderately (n = 29)         | 62.1    | 65.5 | 58.6    |
| Poorly (n = 7)              | 57.1    | 42.9 | 14.3    |
| P value                     | 0.854   | 0.064| 0.025   |
| **pT category**             |         |      |         |
| T1–T2 (n = 15)              | 26.7    | 26.7 | 26.7    |
| T3 (n = 27)                 | 77.8    | 70.4 | 55.6    |
| P value                     | 0.001   | 0.006| 0.071   |
| **pN category**             |         |      |         |
| N0–N1 (n = 34)              | 52.9    | 44.1 | 32.4    |
| N2 (n = 8)                  | 87.5    | 100  | 100     |
| P value                     | 0.056   | 0.001| 0.000   |
| **Smoking**                 |         |      |         |
| Smoker (n = 18)             | 44.4    | 55.6 | 44.4    |
| Non-smoker (n = 23)         | 62.5    | 52.2 | 43.5    |
| P value                     | 0.105   | 0.829| 0.951   |
| **Alcohol**                 |         |      |         |
| Drinker (n = 9)             | 44.4    | 33.3 | 33.3    |
| Non-drinker (n = 32)        | 62.5    | 59.4 | 46.9    |
| P value                     | 0.450   | 0.260| 0.706   |

*clinical data was not available for one patient.
doi:10.1371/journal.pone.0103162.t004
many kinds of tumors, including non-small cell lung cancer [28], meningiomas [32], breast cancer [33,34], renal clear cell carcinoma [35], and ovarian cancer [36]. Restoration of EPB41L3 expression in non-small cell lung cancer or breast cancer cell lines significantly suppressed cell growth in vitro [28,33], and re-expression of EPB41L3 can induce extensive apoptotic cell death in ovarian cancer cells [36]. Recent studies show that the promoter methylation of EPB41L3, leading to loss of its expression, is an important molecular event in several types of tumor cells, whereas EPB41L3 expression can be restored by a demethylating agent [23,34,37]. Nevertheless, the promoter methylation of EPB41L3 and the function of this gene has not been investigated in ESCC. By combination analysis of the methylation array data and expression data, we found 13 hypermethylated CpG sites in the promoter region of EPB41L3 and a greater than ten fold change in down-regulation upon comparison between tumor tissues and normal tissues. This result suggests in ESCC the expression of EPB41L3 is decreased due to its promoter methylation, which is consistent with the previous studies in other types of tumors [23,34,37].

Our results show that the promoter methylation frequency of EPB41L3 in tumor tissues is significantly higher than in the adjacent normal surrounding tissues (59.5% vs. 4.8%, P<0.001). Similar results were observed in non-small cell lung cancer and cervical cancer [23,38]. We also found that the methylation frequency of EPB41L3 is associated with tumor size and the frequency is higher in larger tumors (≥5 cm) than in smaller tumors (<5 cm) (P = 0.044). This result suggests that the methylation of EPB41L3 may be involved in the proliferation of cancer cells. In addition, our results show that 77.8% of the pT3 samples are methylated, which is significantly higher than 26.7% in pT1-pT2 samples (P = 0.001). This result suggests that the methylation of EPB41L3 may play an important role in ESCC tumor invasion.

Glutathione peroxidase 3 (GPX3) catalyzes the reduction of peroxides at the expense of glutathione and protects cells against oxidative damage. Thus, the silencing of GPX3 may impair defenses against endogenous and exogenous genotoxic compounds, which could increase gene mutation rates. GPX3 has been found to be frequently hypermethylated in prostate cancer [39], esophageal adenocarcinoma [40,41], and gastric cancer [42,43]. Furthermore, the promoter hypermethylation of GPX3 was correlated with the down-regulation of mRNA and/or protein expression. In addition, the mRNA expression can be restored by demethylating agents [41-43]. Moreover, suppressive activity of tumor growth and metastasis was demonstrated by both in vitro and in vivo studies [39]. Our result showed that the methylation frequency in tumor tissues is 54.8%, which is significantly higher than 9.5% in paired adjacent normal surrounding tissues. This result is consistent with a previous study that found that the methylation of GPX3 promoter was more frequent in ESCC tumor tissues (71.4%) than in adjacent nontumor tissues (10.7%) [44]. In addition, we analyzed the correlation of the methylation of GPX3 promoter and clinico-parameter of the patients. We found that the frequency of methylation is higher in pT3 patients and pN2 patients compared with pT1-T2 and pN0-N1 patients. These results suggest that the methylation of GPX3 may be involved in the progression and lymphoid metastasis in ESCC.

COL14A1 is a large extracellular matrix glycoprotein associated with mature collagen fibrils. Alterations in extracellular matrix composition have been implicated in tumor progression and metastasis. COL14A1 interacts with decorin [45], a small leucine-rich proteoglycan, which has incrementally been shown to be a powerful inhibitor of growth in a wide variety of tumor cells. This effect is specifically mediated by the interaction of decorin core protein with the epidermal growth factor receptor (EGFR) and other ErbB family proteins [46]. Previous studies have shown that aberrant COL14A1 DNA methylation has been tested in renal cancer cell lines and primary renal cancers, and the methylation correlated with silencing or down-regulating of mRNA expression [47,48]. Moreover, RNAi-induced reduced expression of COL14A1 resulted in the growth of renal cancer cells in vitro [48]. In our study, we observed that the methylation frequency of COL14A1 was significantly higher in tumor tissues than that in adjacent normal surrounding tissues (P = 0.001). We further analyzed the correlation between the methylation status of COL14A1 and the clinico-parameters. We found that the moderate pathologically differentiated samples have a higher methylation frequency of COL14A1, compared with well or poor pathologically differentiated samples. In addition, we also found that the frequency of COL14A1 was 100% in pN2 patients, which was higher than 32.4% in pN0-N1 patients (P<0.001). This result suggests that aberrant methylation of COL14A1 may be associated with the lymph node metastasis of ESCC.

Detecting cell-free nucleic acid in plasma or serum could be useful for numerous diagnostic applications and might prevent the need for tumor tissue biopsies. The release of nucleic acids into the blood is thought to be related to the apoptosis and necrosis of cancer cells in the tumor microenvironment. Secretion has also been suggested as a potential source of the nucleic acids [49]. Changes in the levels of circulating nucleic acids have been associated with tumor burden and malignant progression. Several studies have revealed the presence of methylated DNA in the serum or plasma of patients with various types of malignancy, including bladder cancer, breast cancer, cervical cancer, colorectal cancer, hepatocellular carcinoma, lung cancer, non-Hodgkin

---

**Table 5. Frequency of Promoter Methylation For Individual Genes in Blood Plasma of Esophageal Squamous Cell Carcinoma Patients and Controls. (n = 92).**

| Genes   | Frequency of Methylation (%) | P value |
|---------|------------------------------|---------|
|         | TBP†                         | NBP‡    |
| EPB41L3 | 31.0                         | 0       | 0.000*   |
| GPX3    | 40.5                         | 0       | 0.000*   |
| COL14A1 | 31.0                         | 0       | 0.000*   |

†TBP, blood plasma of tumor patients; ‡NBP, blood plasma of normal healthy individuals; * statistical significance after multiple testing (P<0.01).

doi:10.1371/journal.pone.0103162.t005

**Identifying ESCC Methylome Profile and Potential Plasma Biomarkers**

Detecting cell-free nucleic acid in plasma or serum could be useful for numerous diagnostic applications and might prevent the need for tumor tissue biopsies. The release of nucleic acids into the blood is thought to be related to the apoptosis and necrosis of cancer cells in the tumor microenvironment. Secretion has also been suggested as a potential source of the nucleic acids [49]. Changes in the levels of circulating nucleic acids have been associated with tumor burden and malignant progression. Several studies have revealed the presence of methylated DNA in the serum or plasma of patients with various types of malignancy, including bladder cancer, breast cancer, cervical cancer, colorectal cancer, hepatocellular carcinoma, lung cancer, non-Hodgkin
lymphoma, melanoma, ovarian cancer, pancreatic cancer, and prostate cancer [49]. In our study of the methylation status of EPB41L3, GPX3 and COL14A1 in the plasma of ESCC patients and healthy individuals, the methylation frequencies of these genes are all greater than 30% in the plasma of the ESCC patients. However, absolutely no methylation was found in the plasma of healthy individuals, which may be due to several reasons and not a true case. One limitation of our study is that we used MSP as test method here, which is not quantitative and not sensitive enough to find low-level methylation DNA. There is a report of abnormal methylation detected with MethyLight method in healthy individuals’ plasma [21]. Another reason is that we only tested 50 normal individuals which is a relatively small sample size. In addition, we found that the methylation frequency of GPX3 and COL14A1 are higher in the pT3 patients compared with pT1–pT2 patients, and the methylation frequency of EPB41L3 is higher in pN2 patients than in pN0–pN1 patients. These results indicate that not only there are obvious significant difference of

| Table 6. Correlation between Blood Plasma DNA Hypermethylation and Clinico-pathological Parameters of Esophageal Squamous Cell Carcinoma Patients (n = 42). |
|-----------------------------------------------|
| Frequency of methylation (%)                  |
|                                               |
| EPB41L3 | GPX3 | COL14A1 |
| Gender                                         |
| Male (n = 27)                                  |
| 29.6    | 33.3 | 25.9    |
| Female (n = 15)                                |
| 33.3    | 53.3 | 40.0    |
| P value                                        |
| 1.000   | 0.206| 0.488   |
| Age group (year)                              |
| < 60 (n = 11)                                  |
| 27.3    | 54.5 | 18.2    |
| ≥60 (n = 31)                                  |
| 32.3    | 35.5 | 35.5    |
| P value                                        |
| 1.000   | 0.305| 0.453   |
| Family history                                |
| Yes (n = 17)                                   |
| 32.0    | 40.0 | 24.0    |
| No (n = 25)                                    |
| 29.4    | 41.2 | 41.2    |
| P value                                        |
| 0.859   | 0.939| 0.237   |
| Tumor size                                     |
| < 5 (n = 27)                                   |
| 29.6    | 29.6 | 25.9    |
| ≥5 (n = 15)                                    |
| 33.3    | 60.0 | 40.0    |
| P value                                        |
| 1.000   | 0.055| 0.488   |
| Differentiation                                |
| Well (n = 6)                                   |
| 0       | 16.7 | 16.7    |
| Moderate (n = 29)                              |
| 37.9    | 44.8 | 37.9    |
| Poor (n = 7)                                   |
| 28.6    | 42.9 | 14.3    |
| P value                                        |
| 0.078   | 0.400| 0.312   |
| pT category                                    |
| T1–T2 (n = 15)                                 |
| 26.7    | 20.0 | 6.7     |
| T3 (n = 27)                                    |
| 33.3    | 51.9 | 44.4    |
| P value                                        |
| 0.739   | 0.044| 0.015   |
| pN category                                    |
| N0–N1 (n = 34)                                 |
| 17.6    | 35.3 | 29.4    |
| N2 (n = 8)                                     |
| 87.5    | 62.5 | 37.5    |
| P value                                        |
| 0.000   | 0.235| 0.686   |
| Smoking Status*                                |
| Smoker (n = 18)                                |
| 27.8    | 33.3 | 27.8    |
| Nonsmoker (n = 23)                             |
| 30.4    | 47.8 | 34.8    |
| P value                                        |
| 0.853   | 0.350| 0.632   |
| Alcohol Consumption*                           |
| Drinker (n = 9)                                |
| 11.1    | 33.3 | 22.2    |
| Nondrinker (n = 32)                            |
| 34.4    | 43.8 | 34.4    |
| P value                                        |
| 0.240   | 0.711| 0.692   |

*clinical data was not available for one patient.
doi:10.1371/journal.pone.0103162.006
aberrant DNA methylation of EPB41L3, GPX3 and COL14A1 in the plasma between ESCC patients and healthy individuals, but also the methylation frequency might be associated with the advanced tumor stages. Moreover, we also evaluated the methylation status of the 3 genes in plasma for the diagnosis of ESCC using ROC curve analysis. We found that the sensitivities of the methylated genes in plasma DNA range from 31% to 40.5%. A previous study reported that diagnostic information could be increased if methylation of multiple genes in cell-free DNA were analyzed in combination [21]. Indeed, we found that combination analysis of the three genes increased the sensitivity to 64.3%. The sensitivity of the 3 genes for use as early diagnosis tools is not high enough in this study. The combination of more methylated genes may increase the diagnostic sensitivity. These data indicated that combinatorial methylation analysis of these genes in plasma DNA has the potential to be a valuable diagnostic tool of noninvasive testing. The utility of these plasma biomarkers in the clinical setting needs further study in a larger population and with more accurate methods like bisulfite pyrosequencing.

**Author Contributions**

Conceived and designed the experiments: YZ JZ. Performed the experiments: XL FZ CJ VW. Analyzed the data: YL FY. Contributed reagents/materials/analysis tools: FZ NW HY. Contributed to the writing of the manuscript: YZ JZ XL.

**References**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2093–2107.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
3. Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, et al. (2012) FOXM1 induces a global DNA methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One 7: e34329.
4. Baba Y, Watanabe M, Baba H (2013) A review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surgery today.
5. Kaz AM, Grady WM (2014) Epigenetic biomarkers in esophageal cancer. Cancer Lett 342: 193–199.
6. Kurou F, Traposco F, Vaydarami S, Matsuyama A, Alder H, et al. (2003) Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63: 3724–3728.
7. Roth MJ, Abnet CC, Hu N, Wang QH, Wei WQ, et al. (2006) p16, MGMT, RARBeta2, CLDN3, CRBP, and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep 15: 1591–1597.
8. Mizuiri H, Yoshida K, Toge T, Oue N, Aung PP, et al. (2005) DNA methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutH homolog 2 in esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 130: 1371.
9. Wang J, Casco AJ, Fu C, Xue H, Guo G, et al. (2008) Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 17: 118–125.
10. Nie Y, Liao J, Zhao X, Song Y, Yang GY, et al. (2002) Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 23: 1713–1720.
11. Zhang L, Lu W, Xiao X, Xing D, Tan W, et al. (2003) Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis 24: 1039–1044.
12. Tzao C, Hsu HS, Sun GH, Lai HL, Wang YC, et al. (2005) Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutH homolog 2 in esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 130: 1371.
13. Takeno S, Noguchi T, Fumoto S, Kimura Y, Shihata T, et al. (2004) E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Ann Surg Oncol 11: 72–78.
14. Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, et al. (2005) Metallothionein 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 4: 42.
15. Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH (2005) Expression of EGR4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol 9: 1174–1178.
16. Hamilton JP, Sato F, Jin Z, Greenland BD, Io T, et al. (2006) Reprimo methylation is a potential biomarker of Barrett’s-Associated esophageal neoplastic progression. Clin Cancer Res 12: 6637–6642.
17. Kawakami K, Brabender J, Lord RV, Greshon S, Greenland BD, et al. (2000) Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92: 1805–1811.
18. Mandelker DL, Yamashita K, Tomokaru Y, Mimori K, Howard DL, et al. (2005) FGFR5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65: 4963–4968.
19. Lima SC, Hernandez-Vargas H, Simao T, Durand G, Kruel CD, et al. (2011) Identification of a DNA methylation signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics 6: 1217–1227.
20. Bhikova M, Barnes B, Tsai C, Ho V, Kastale B, et al. (2011) High density DNA methylation array with single CpG site resolution. Genomics 98: 289–295.
21. Li B, Wang B, Niu LJ, Jiang L, Qiu CC (2011) Hypermethylation of multiple tumor-related genes associated with DNA methylation up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics 6: 367–368.
22. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821–9826.
23. Heller G, Fong KM, Girard L, Sell S, End-Pfutzenreuter A, et al. (2006) Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 25: 959–968.
24. Li LC, Dahlia R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427–1431.
25. Hu N, Cliffورد RJ, Yang HH, Wang C, Goldstein AM, et al. (2010) Genome-wide analysis of DNA copy number neutral loss of heterozygosity (CNNOLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genomics 11: 576.
26. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547–1548.
27. Simon R, Lam A, Li MC, Negan M, Meneses S, et al. (2007) Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 3: 11–17.
28. Tran YK, Bogler O, Giese KM, Wieland I, Green MI, et al. (1999) A novel esophageal cancer-related gene, downregulated by CpG island methylation array with single CpG site resolution. Genomics 28: 289–295.
29. Bernkopf DB, Williams ED (2008) Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets 12: 843–853.

**Table 7. Diagnostic Information of Plasma DNA Methylation of Individual Genes.**

| Gene       | AUC* (95%, CI) | Sensitivity (%) | Specificity (%) |
|------------|---------------|----------------|-----------------|
| EPB41L3    | 0.655 (0.539–0.770) | 31.0 | 100 |
| GPX3       | 0.702 (0.591–0.814) | 40.5 | 100 |
| COL14A1    | 0.655 (0.539–0.770) | 31.0 | 100 |
| Any of the 3 genes | 0.821 (0.727–0.916) | 64.3 | 100 |

*AUC, area under ROC curve; CI, confidence interval.*

doi:10.1371/journal.pone.0103162.t007
30. Robb VA, Li W, Gutmann DH (2004) Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression. Oncogene 23: 3589–3596.
31. Darling DL, Yingling J, Wynshaw-Boris A (2005) Role of 14-3-3 proteins in eukaryotic signaling and development. Curr Top Dev Biol 68: 281–315.
32. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, et al. (2000) Loss of DAL-1, a protein 4.1-related tumor supressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 9: 1495–1500.
33. Charboneau AL, Singh V, Yu T, Newsham IF (2002) Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer 100: 181–188.
34. Heller G, Gerads J, Ziegler B, Newsham I, Filipits M, et al. (2006) Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer 118: 916–923.
35. Dafoe D, Bran B, Sinclair J, Lavrenson K, Benjamin EC, et al. (2010) Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia 12: 579–589.
36. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, et al. (2006) Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66: 5021–5028.
37. Morris MR, Ricketts C, Gentle D, Abdulsalam M, Clarke N, et al. (2010) Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29: 2104–2117.
38. Schwarzenbach H, Hoon DS, Panket K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426–437.